Literature DB >> 18615116

Augmentation of AAV-mediated cardiac gene transfer after systemic administration in adult rats.

O J Müller1, S Schinkel, J A Kleinschmidt, H A Katus, R Bekeredjian.   

Abstract

Adeno-associated virus (AAV)-6 or -9-pseudotyped vectors are suitable for efficient cardiac gene transfer after intravenous injection in mice. However, a systemic application in larger animals or humans would require very high doses of viral particles. Therefore, the aim of our study was to test if ultrasound-targeted microbubble destruction could augment cardiac transduction of AAV vectors after intravenous administration in rats. To analyze efficiency and specificity of gene transfer, microbubbles loaded with AAV-6 or -9 harboring a luciferase or enhanced green fluorescent protein (EGFP) reporter gene were infused into the jugular vein of adult Sprague-Dawley rats. During the infusion, high mechanical index ultrasound was administered to the heart. Control rats received the same amount of virus without microbubbles, but with ultrasound. After 4 weeks, organs were harvested and analyzed for reporter gene expression. In contrast to low cardiac expression after systemic transfer of the vector solution without microbubbles, ultrasound-targeted destruction of microbubbles significantly increased cardiac reporter activities between 6- and 20-fold. Analysis of spatial distribution of transgene expression using an AAV-9 vector encoding for EGFP revealed transmural expression predominantly in the left ventricular anterior wall. In conclusion, ultrasound targeted microbubble destruction augments cardiac transduction of AAV vectors in rats. This approach may be suitable for efficient, specific and noninvasive AAV-mediated gene transfer in larger animals or humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18615116     DOI: 10.1038/gt.2008.111

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  23 in total

Review 1.  Endogenous migration modulators as parent compounds for the development of novel cardiovascular and anti-inflammatory drugs.

Authors:  Wolfgang Poller; Madlen Rother; Carsten Skurk; Carmen Scheibenbogen
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  S100A1 DNA-based Inotropic Therapy Protects Against Proarrhythmogenic Ryanodine Receptor 2 Dysfunction.

Authors:  Julia Ritterhoff; Mirko Völkers; Andreas Seitz; Kristin Spaich; Erhe Gao; Karsten Peppel; Sven T Pleger; Wolfram H Zimmermann; Oliver Friedrich; Rainer H A Fink; Walter J Koch; Hugo A Katus; Patrick Most
Journal:  Mol Ther       Date:  2015-05-25       Impact factor: 11.454

Review 3.  Targeted gene therapy for the treatment of heart failure.

Authors:  Kleopatra Rapti; Antoine H Chaanine; Roger J Hajjar
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

Review 4.  The present and future role of ultrasound targeted microbubble destruction in preclinical studies of cardiac gene therapy.

Authors:  Lijun Qian; Barsha Thapa; Jian Hong; Yanmei Zhang; Menglin Zhu; Ming Chu; Jing Yao; Di Xu
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

5.  Critical role of RAGE and HMGB1 in inflammatory heart disease.

Authors:  Anna Bangert; Martin Andrassy; Anna-Maria Müller; Mariella Bockstahler; Andrea Fischer; Christian H Volz; Christoph Leib; Stefan Göser; Sevil Korkmaz-Icöz; Stefan Zittrich; Andreas Jungmann; Felix Lasitschka; Gabriele Pfitzer; Oliver J Müller; Hugo A Katus; Ziya Kaya
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-29       Impact factor: 11.205

6.  A proteolytic fragment of histone deacetylase 4 protects the heart from failure by regulating the hexosamine biosynthetic pathway.

Authors:  Lorenz H Lehmann; Zegeye H Jebessa; Michael M Kreusser; Axel Horsch; Tao He; Mariya Kronlage; Matthias Dewenter; Viviana Sramek; Ulrike Oehl; Jutta Krebs-Haupenthal; Albert H von der Lieth; Andrea Schmidt; Qiang Sun; Julia Ritterhoff; Daniel Finke; Mirko Völkers; Andreas Jungmann; Sven W Sauer; Christian Thiel; Alexander Nickel; Michael Kohlhaas; Michaela Schäfer; Carsten Sticht; Christoph Maack; Norbert Gretz; Michael Wagner; Ali El-Armouche; Lars S Maier; Juan E Camacho Londoño; Benjamin Meder; Marc Freichel; Hermann-Josef Gröne; Patrick Most; Oliver J Müller; Stephan Herzig; Eileen E M Furlong; Hugo A Katus; Johannes Backs
Journal:  Nat Med       Date:  2017-12-11       Impact factor: 53.440

Review 7.  Nucleic acid delivery with microbubbles and ultrasound.

Authors:  Joshua J Rychak; Alexander L Klibanov
Journal:  Adv Drug Deliv Rev       Date:  2014-01-31       Impact factor: 15.470

Review 8.  AAV vectors for cardiac gene transfer: experimental tools and clinical opportunities.

Authors:  Christina A Pacak; Barry J Byrne
Journal:  Mol Ther       Date:  2011-07-26       Impact factor: 11.454

Review 9.  Promise of adeno-associated virus as a gene therapy vector for cardiovascular diseases.

Authors:  Abesh Bera; Dwaipayan Sen
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

10.  AAV-9 mediated phosphatase-1 inhibitor-1 overexpression improves cardiac contractility in unchallenged mice but is deleterious in pressure-overload.

Authors:  D M Schwab; L Tilemann; R Bauer; M Heckmann; A Jungmann; M Wagner; J Burgis; C Vettel; H A Katus; A El-Armouche; O J Müller
Journal:  Gene Ther       Date:  2018-01-19       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.